Hematology
Hematology
Advertisement
Andrew MorenoMDS | October 30, 2024
A retrospective study's insights help inform timing decisions regarding allogenic HCT in patients with MDS or CMML.
Read More
Patrick DalyMDS | October 30, 2024
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
Julie GouldMDS | October 29, 2024
The COMMANDS trial data underscore luspatercept as the preferred treatment for disease not previously exposed to ESAs.
Hamda Khan, MASickle Cell Disease | October 25, 2024
A cohort lifetime study from Hamda Khan, MA, and Jason Hodges, PhD, MA, follows patients from pediatric into adult SCD care.
Andrew MorenoMDS | October 21, 2024
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Andrew MorenoMDS | October 17, 2024
Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.
Andrew MorenoMDS | October 22, 2024
A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.
Surbhi Sidana, MDHematology | October 22, 2024
A recent study brings insight regarding the best timing for this CAR-T therapy in patients with prior BCMA-directed therapy.
Theodore Wun, MDSickle Cell Disease | October 22, 2024
Dr. Theodore Wun and Dr. Olubusola Oluwole investigated the causes of rising stroke rates among pediatric and adult patients.
Andrew MorenoMyelofibrosis | October 3, 2024
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
Andrew MorenoHemophilia | October 3, 2024
A new study addresses the need for data on treatment outcomes in patients younger than 12 years of age.
Andrew MorenoMDS | September 18, 2024
Levels for certain inflammation biomarkers in patients with MDS were similar to in patients with autoinflammatory disorders.
Andrew MorenoMDS | September 18, 2024
In pediatric, adolescent, and young adult patients, hematopoietic stem cell transplant was found to bolster overall survival.
Andrew MorenoMDS | September 18, 2024
The most common serious treatment-emergent adverse event among patients receiving either therapy was pneumonia.
Andrew MorenoHematology | September 4, 2024
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Andrew MorenoThalassemia | September 4, 2024
Differences were identified between patient racial groups and by urban versus rural populations.
Andrew MorenoThalassemia | September 4, 2024
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
Patrick DalyPNH | September 4, 2024
Lactate dehydrogenase level was pinpointed as a significant predictor of thromboembolism and mortality.
Tamara Diesch-Furlanetto, MDSickle Cell Disease | September 3, 2024
A study has assessed cryogenically preserved ovarian tissue samples from women with SCD for any effects from hydroxyurea.
Andrew MorenoPNH | August 31, 2024
A multicenter, double-blind, randomized study found no clinically significant difference in efficacy or safety.
Advertisement
Advertisement
Advertisement
Latest News

October 30, 2024